In murine tumor models, surrogate antibodies of Tiragolumab elicited inflammation in TAMs, monocytes, and DCs via Fcγ receptors (FcγR), facilitating the transition of anti-tumor CD8+ T cells from an exhausted effector-like state to a memory-like state. Here, CD8A is linked to neoplasm.